Skip to main content

Table 2 Secondary outcomes of the study

From: Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial

 

SZC group (n = 60)

SPS group (n = 60)

Comparison bet. gps. at baseline

Comparison bet. gps. at week 8

Baseline

Week 8

P0

Baseline

Week 8

p0

P1

P2

Interdialytic weight gain (kg)

3.0 (2.0–4.2)

3.0 (2.0–4.0)

0.205

3.0 (2.5–3.5)

3.0 (2.0–4.0)

0.624

0.997

0.793

BP (mmHg)

        

 - Systolic BP

134.4 ± 25.1

136.4 ± 16.7

0.636

 

136.3 ± 18.4

138.5 ± 17.3

0.506

 

0.664

0.540

 - Diastolic BP

79.3 ± 14.6

81.2 ± 9.6

0.369

 

80.7 ± 10.9

82.3 ± 9.8

0.415

 

0.590

0.552

Need for rescue therapy (No)

-

2 (3.3%)

NA

-

4 (6.6%)

NA

-

0.678

Albumin (g/dl)

3.8 ± 0.3

3.8 ± 0.4

0.634

3.7 ± 0.4

3.7 ± 0.5

0.765

0.218

0.387

Serum electrolytes

        

 Sodium (mEq/L)

136.1 ± 15.8

138.4 ± 4.1

0.324

136.1 ± 3.8

137.5 ± 3.7

0.074

0.993

0.266

 Calcium (mg/dl)

8.9 ± 1.1

9.1 ± 1.3

0.357

9.2 ± 0.9

9.2 ± 1.3

0.892

0.078

0.604

 Phosphorus (mg/dl)

5.8 (4.9–7.0)

5.2 (3.7 − 7.3)

0.440

6.0 (5.3–6.6)

5.6 (4.3 − 7.4)

0.881

0.779

0.387

  1. Normally quantitative data were expressed as Mean ± standard deviation (SD) while non-normally quantitative data were expressed as Median with interquartile ranges (IQR), or absolute numbers as appropriate
  2. tp0: p value for comparing between baseline and week 8 in each group; p1: p value for for comparison bet. groups at baseline; p2: p value for for comparison bet. groups at week 8; *: Statistically significant at p ≤ 0.05; BP: blood pressure